Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Convection Enhanced Delivery in the Setting of High-Grade Gliomas

Version 1 : Received: 11 March 2021 / Approved: 12 March 2021 / Online: 12 March 2021 (15:01:51 CET)

How to cite: Nwagwu, C.D.; Immidisetti, A.V.; Jiang, M.; Adeagbo, O.; Adamson, D.C.; Carbonell, A. Convection Enhanced Delivery in the Setting of High-Grade Gliomas. Preprints 2021, 2021030342 (doi: 10.20944/preprints202103.0342.v1). Nwagwu, C.D.; Immidisetti, A.V.; Jiang, M.; Adeagbo, O.; Adamson, D.C.; Carbonell, A. Convection Enhanced Delivery in the Setting of High-Grade Gliomas. Preprints 2021, 2021030342 (doi: 10.20944/preprints202103.0342.v1).

Abstract

Development of effective treatments for high-grade glioma (HGG) is hampered by 1) the blood-brain barrier (BBB), 2) an infiltrative growth pattern, 3) rapid development of therapeutic resistance, and, in many cases, 4) dose-limiting toxicity due to systemic exposure. Convec-tion-enhanced delivery (CED) has the potential to significantly limit systemic toxicity and in-crease therapeutic index by directly delivering homogenous drug concentrations to the site of disease. In this review, we present clinical experiences and preclinical developments of CED in the setting of high-grade gliomas.

Subject Areas

glioblastoma; high-grade glioma; refractory glioma; direct delivery; convection enhanced delivery; neuro-oncology; refractory glioblastoma; clinical trials

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.